Résumé
Le nitroprussiate de soude est utilisé comme vasodilatateur puissant chez l’homme depuis 1929. A partir de communications à propos de trois décès reliés au NPS on retient: l’acidose grave et le taux de dosage élevé de nitroprussiate de soude. Ces derniers effets peuvent se rencontrer chez des cas de réponses anormales, non-mortelles au nitroprussiate de soude.
La réponse à l’action du nitroprussiate de soude est l’une des suivantes:
-
Normale 1.
vasodilation à bas taux de dosage (<10 µg/kg/min)
-
Anormale 2.
vasodilatation à haut taux de dosage (>10µg/kg/min)
-
3.
tachyphylaxie
-
4.
résistance
La manifestation anormale de l’action du nitroprussiate de soude est une des suivantes:
-
-reaction physiologique excessive (rénine-angiotensine-aldostérone), traité par blocage beta ou ganglioplégie;
-
-acidose et accumulation de cyanure de la biotransformation du NPS, traité comme une intoxication au cyanure.
On donne le canduite à suivre pour l’ultilisation súre de nitroprussiate de soude les contre-incations, l’administration du nitroprussiate de soude, la surveillance requise, la conduite à tenir face aux reactions anormales.
Article PDF
Avoid common mistakes on your manuscript.
References
Johnson, C.C. The actions and toxicity of sodium nitroprusside, Arch. Int. Pharmacodyn. Therap.35: 480 (1929).
Moraca, P.P., Bitte, E.M., Hale, D.E.,et al. Clinical evaluation of sodium nitroprusside as a hypotensive agent, Anesthesiology23: 193 (1962).
Chatterjee, K., Parmley, W.W., Ganz,et al. Hemodynamic and metabolic responses to vasodilator therapy in acute myocardial infarction, Circulation48: 1183 (1973).
Carlixer, N.H., Dexuxe, D.P., Finch, C.S.,et al. Sodium nitroprusside to treat ergota-mine induced peripheral ischemia, J.A.M.A.227: 3, 308 (1974).
Kreye, V.A.W., Baron, G.P., Lüth, J.B.,et al. Mode of action of sodium nitroprusside on vascular smooth muscle, Naunyn-Schmiedeberg’s Arch. Pharmacol.288: 381 (1975).
Jack, R.D. Toxicity of sodium nitroprusside, B.J.A.46: 952 (1974).
Merrifield, A.J. &Bluxdell, M.D. Toxicity of sodium nitroprusside, B.J.A.46: 324 (1974).
Davies, D.W., Kadar, D., Steward, D.J.,et al. A sudden death associated with the use of sodium nitroprusside for induction of hypotension during anaesthesia, Canada. Anaesth. Soc. J.,22: 547 (1975).
McCrae, W.R. &Owen, Mary Severe metabolic acidosis following hypotension induced with sodium nitroprusside, B.J.A.46: 795 (1974).
McDowall, D.G., Keaney, N.P., Turner, J.E.,et al. The toxicity of sodium nitroprusside, B.J.A.46: 327 (1974).
Davies, D.W., Greiss, L., &Kadar, D. Metabolic observations during normal and abnormal responses to sodium nitroprusside during anaesthesia in children, Canada. Anaesth. Soc.J.22: 553 (1975).
Vesey, C.J., Cole, P.V., Linnel, J.C.,et al. Some metabolic effects of sodium nitroprusside in man, B.M.J.2: 140 (1974).
Taylor, T.H., Styles, M., &Lamming, A.J. Sodium nitroprusside as a hyportensive agent in general anaesthesia, B.J.A.42: 859 (1970).
Davies, D.W., Tremblay, N.G., &Kadar, D. Work in progress, Research Institute of the Hospital for Sick Children, Toronto.
Davies, D.W. - personal communication, The Hospital for Sick Children, Toronto.
Greiss, L. - personal communication, Sunnybrook Medical Centre, Toronto.
Tuzel, I.H. Sodium nitroprusside: A review of its clinical effectiveness as a hypotensive agent. J, Clin. Pharmacol. 494 (1974).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Greiss, L., Tremblay, N.A.G. & Davies, D.W. The toxicity of sodium nitroprusside. Canad. Anaesth. Soc. J. 23, 480–485 (1976). https://doi.org/10.1007/BF03005976
Issue Date:
DOI: https://doi.org/10.1007/BF03005976